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Treatment strategies are provided in accordance with the level of global cardiovascular risk, from lifestyle
modification in the lower risk group to more comprehensive treatment in the higher risk group. Considering the
common trend of combination drug regimen, the choice of the first drug is suggested more liberally according to
the physician’s discretion.
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The purpose of hypertension (HTN) treatment is to pre-
vent cardiovascular disease (CVD) caused by increased
blood pressure (BP) and decrease mortality by control-
ling high BP. In patients who already have established
CVD, treatment aims to control BP to prevent progres-
sion or recurrence of disease in order to decrease
mortality and improve quality of life. HTN treatment
provides greater benefit in patients who are at higher
risk for CVD. Most clinical studies of HTN have found
that lowering systolic blood pressure (SBP) by approxi-
mately 10 to 20 mm Hg or diastolic blood pressure
(DBP) by approximately 5 to 10 mm Hg can reduce the
occurrence of stroke by 30% to 40% and that of ischemic
heart disease by 15% to 20% [1]. Because most clinical
studies were performed over a relatively short period,
the benefits of HTN treatment over a period of 5 years
or more seem to be much more pronounced than the
treatment efficacy observed in clinical studies. The bene-
fits of HTN treatment are not affected by sex or age and* Correspondence: scchae@knu.ac.kr
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elderly. HTN treatment was found to be the most cost-
effective intervention for prevention of CVD.Strategy for hypertension treatment
If a patient is already known to have high BP, the diag-
nosis of HTN must be confirmed prior to treatment by
measuring the out-of-clinic BP, such as at home or using
24-h monitoring. Measurement of out-of-clinic BP helps
not only to obtain a more accurate diagnosis but also to
determine the appropriate treatment for the patient and
to increase treatment compliance. If HTN is diagnosed,
the risk factors for CVD, associated diseases, and exist-
ence of hypertensive complications should be investi-
gated (Figure 1). Patients with white coat HTN, which is
defined as high BP in but not out of the clinic, must be
followed up periodically at 3- to 6-month intervals be-
cause their risk of CVD increases over time. HTN treat-
ment must include nondrug therapy (such as lifestyle
modification) concomitant with drug therapy. The initi-
ation of drug therapy needs to be considered and deter-
mined on the basis of not only the BP level but also the
presence of risk factors for CVD and evidence of damage
to target organs. Drug therapy may be used in patients
with a BP of 140/90 mm Hg or higher regardless of theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Treatment strategies for hypertension. BP blood pressure; CV cardiovascular; HTN hypertension. ± Optional. *Recommended test. †In
the moderate to high risk group, drug therapy can be considered for stage 2 hypertension patients.
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quality of life of patients with HTN can be affected by
physical and psychological problems caused by HTN,
the main and side effects of the drug, and the relation-
ship between the patient and physician. Adequate com-
munication and provision of information can decrease
the dosage and frequency of medication used, which in-
creases patient compliance, improves the BP control
rate, and promotes continuous treatment.
Initiation of hypertension treatment
Prehypertension stage II
Cardiovascular (CV) mortality caused by HTN increases
twofold for each 20-mm Hg increase in SBP or 10-mm
Hg increase in DBP over the baseline level of 115/
75 mm Hg [1,2]. Therefore, in patients with BP over
120/80 mm Hg, nondrug therapy is recommended toTable 1 Treatment for hypertension according to the risk
Risk factor Blood pressure (mm
Stage 2 prehyperten
(130–139/85–89)
Risk factors 0 Lifestyle modification
Risk factors 1–2 other than DM Lifestyle modification
Risk factors ≥3, subclinical organ damage Lifestyle modification
DM, cardiovascular disease, chronic kidney disease Lifestyle modification
DM diabetic mellitus.
aLifestyle modification is carried within several weeks to 3 months. †Drug therapy m
bDrug therapy may be begun as target blood pressure determined.prevent the occurrence of HTN and CV events. Initi-
ation of drug therapy in patients with stage 2 prehyper-
tension can delay the progression to HTN [3,4], but
there is little evidence for the effectiveness of early inter-
vention in most clinical studies [5]. Initiation of drug
therapy during stage 2 prehypertension showed no con-
sistent benefit in patients with prediabetes [6,7], DM [8],
stroke [9], or coronary artery disease; [10] therefore, the
cost-benefit ratio should be considered in the decision
to use drug therapy (Table 1).
Hypertension stage I
Patients with stage 1 HTN without other risk factors are
in the low-risk group and would not be expected to ob-
tain a greater benefit from treatment [11]. However,
their overall risk will increase over time, and the window
in which treatment could reverse progression might beHg)




















ay be begun immediately according to the height of BPs.
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safe, and drug therapy has been found to be cost-
effective given that patients generally fail to accomplish
lifestyle changes. Drug therapy is recommended only
after measurement of the out-of-clinic BP in order to ex-
clude the possibility of white coat HTN [12,13]. The ef-
fect of medical therapy on white coat HTN has not yet
been proven; however, as white coat HTN poses in-
creased metabolic risk and risk for CV events over the
long term, lifestyle modification is recommended at first,
and patients should be observed periodically for devel-
opment of persistent HTN. Drug therapy should be in-
stituted immediately in patients with high-risk stage I
HTN [14,15].
Hypertension stage II
According to most randomized clinical trials, immediate
drug therapy is warranted in patients with a BP of ≥160/
100 mm Hg due to the noticeable effect of treatment
[5,14,15].
Hypertension in the elderly
The effect of drug therapy against HTN is clear irrespect-
ive of age [16]. Drug therapy can be initiated in elderly pa-
tients when the SBP is 160 mm Hg or higher; consistent
drug therapy can be considered if the SBP is 140 to
159 mm Hg and the patient tolerates the drug well.
Target blood pressure in the treatment of
hypertension
As shown in Table 2, except under specific circum-
stances, the target BP is generally an SBP of less than
140 mm Hg and a DBP of less than 90 mm Hg [5,17,18].
Hypertension in the elderly
The effects of decreasing BP in elderly patients with HTN
are clear, but it is difficult to lower BP to less than
140 mm Hg in such patients [19], and there is no differ-






Uncomplicated hypertension 140 90
Elderly 140–150 90
Diabetes mellitus 140 85
Stroke 140 90
Coronary artery disease 140 90
Chronic kidney disease
Without albuminuriaa 140 90
With albuminuria 130 80
aMicroalbuminuria or macroalbuminuria.Hg. Therefore, the target SBP is approximately 140 to
150 mm Hg with a DBP that is not excessively low, i.e.,
less than approximately 60 mm Hg [20,21].
Hypertension in patients with diabetes
Reduction of BP in patients with HTN and diabetes is
very important for reducing CV complications [22]. Few
studies have shown reduction of SBP to below 130 mm
Hg. Even reduction of SBP to less than 120 mm Hg did
not demonstrate any additional preventive effect on
CVD but rather showed a deleterious effect on renal
function; therefore, the recommended target BP is an
SBP below 140 mm Hg [23] and a DBP below 85 mm
Hg [24].
Hypertension in patients with stroke
HTN is a most important causative risk factor for stroke.
HTN treatment can reduce the recurrence of stroke and
CV events [25-27], but there are no distinct benefits
from reducing SBP to below 130 mm Hg [28]. In par-
ticular, a recent clinical study in patients with cerebral
infarction showed no additional benefit from controlling
SBP below 140 mm Hg [29]. Considering the clinical
studies to date, a target SBP below 140 mm Hg is rec-
ommended in patients with stroke.
Hypertension in patients with coronary artery disease
Reduction of SBP to below 130 mmHg shows no con-
sistent prevention of CVD in patients with HTN and
coronary artery disease [30-32]. Therefore, a target SBP
of below 140 mm Hg is recommended.
Hypertension in patients with chronic kidney disease
The major purpose of controlling BP in patients with
chronic kidney disease (CKD) is to prevent deterioration
of renal function and reduce the occurrence of CVD.
Further control of SBP to below 140 mm Hg has shown
no additional benefit in patients with HTN and CKD
without diabetes [33-35]. However, the data on the goal
of treatment in patients with HTN and CKD with dia-
betes is even more insufficient [36,37]. Meta-analysis has
not proven that a target BP of less than 140 mm Hg is
any more effective at preventing cardiac and renal events
[23,38,39]. Therefore, on the basis of recent clinical data,
a target SBP of less than 140 mm Hg is recommended
regardless of the presence of diabetes. However, a target
SBP below 130 mm Hg can be recommended in patients
with HTN with prominent albuminuria [40].
Low threshold of hypertension treatment
As BP increases, the CV risk also increases, whereas as
BP decreases, the risk of the occurrence of a CV event
decreases to some extent. There is insufficient clinical
data to prove the J-curve hypothesis (a hypothesis that
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than decrease CV events and mortality), but post hoc
analysis of clinical studies suggests the possibility of such
a J-curve effect and a pathophysiological detriment of
excessively low BP [41]. Therefore, it is not recom-
mended to target BP too low, but additional studies are
needed to determine how low a BP is desirable.
Nondrug therapy and lifestyle modification
Nondrug therapy or lifestyle modification, such as adop-
tion of a healthy diet, increasing exercise, smoking cessa-
tion, and moderation of alcohol intake, has shown great
ability to lower BP and is important in all patients with
HTN. Even in patients with prehypertension, nondrug
therapy is strongly recommended to prevent progression
to HTN (Table 3). Healthy lifestyle habits have almost
the same BP-decreasing effect as approximately one dose
of anti-HTN drug [42]. Furthermore, in patients with
HTN who are using medication, adding lifestyle modifi-
cation can reduce the dose and frequency of medication
used, maximize the effect of the drug, and reduce side
effects. Lifestyle improvement also has other beneficial
effects on CV risk in addition to the lowering of BP. Cli-
nicians should remain aware that it is difficult to main-
tain lifestyle modifications long-term or to achieve a
target BP for the HTN in stage II or higher even at best.
Therefore, the clinician should provide encouragement
to continue lifestyle modifications while also educating
the patient in their limitations. In addition, because
adopting several types of lifestyle modification rather
than one alone maximizes the effects, a simultaneous
approach is recommended to meet the goal of minimiz-
ing CVD.
Restriction of salt intake
According to the 2010 KNHANES data, it is estimated













−1.1/−0.9 Each reduction of 1 kg
Moderation in
drink
−3.9/−2.4 Less than two glasses per
day
Exercise −4.9/−3.7 30–50 min per day for
more than 5 days in a week
Diet control −11.4/−5.5 Vegetables-based healthy
diet habit
BP blood pressure.which is a higher amount than western (10 g) or Japa-
nese (10.7 g) populations [43]. Salt intake can increase
the risk for CV events because of the association of cen-
tral hemodynamics with the estimated 24-h urinary so-
dium in patients with HTN [44]. Halving the daily salt
intake of 10.5 g will decrease SBP by 4 to 6 mm Hg
[45,46]. However, there have been variable and confusing
reports about the relationship between salt restriction
and CV events [47-50]. Despite the absence of randomized
large-scale trials, some reports of a J-curve phenomenon
for salt intake and CV events, and lack of Korean data,
there is no clear evidence that salt restriction is harmful,
especially among Koreans with their high-salt intake.
Therefore, we must recommend decreasing salt intake in
accordance with other guidelines [51].
The daily recommended amount of salt is less than 6 g
(sodium [g] × 2.5). Salt reduction has many benefits, in-
cluding lowering of BP and reducing the need for di-
uretics, which cause detrimental urinary loss of potassium
and calcium. The avoidance of urinary calcium loss pre-
vents the development of osteoporosis and renal calculi.
Sensitivity to salt tends to be higher in patients who
are elderly, obese, or have diabetes or family members
with HTN. Greater salt sensitivity means a greater re-
duction in BP in response to salt restriction. The dietary
habits must be modified. Some recommendations are
not to put additional salt on the table during the meal
and to avoid high-salt processed foodstuffs. Some fre-
quently eaten foods, such as kimchi, stew, soup, salted
fermented seafood, instant ramen, and dry bar snacks
containing meat and fish, are very salty. When cooking
foods, natural ingredients should be used instead of syn-
thetic flavoring agents. The patient should not only re-
duce absolute salt intake but also try to consume more
low-salt foods.
Weight reduction
HTN is closely related to obesity, and weight reduction de-
creases BP. Central obesity in particular is closely associated
with HTN, dyslipidemia, diabetes, and CV death. In a pa-
tient heavier than 110% of ideal body weight, weight reduc-
tion of only 5 kg can decrease BP. The beneficial effects of
weight reduction are higher in patients with diabetes, dys-
lipidemia, and left ventricular hypertrophy (LVH). The
combination of weight reduction with exercise, moderation
of alcohol consumption, and reduction of salt intake has
synergistic effects on BP. The recommended initial goal of
weight reduction is 4 to 5 kg, with an additional 5 kg reduc-
tion after the initial goal has been achieved.
The ideal body mass index (BMI) (weight [kg]/height
[m]2) varies among reports and according to nationality.
A collaborative analysis reported that BMI either above or
below the apparent optimum of approximately 22.5 to
25 kg/m2 is itself a strong predictor of overall mortality
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and grade 1 obesity were associated with significantly
lower all-cause mortality [53]. A report on data from 1.2
million Koreans revealed that the risk of death from any
cause was lowest among patients with a BMI of 23.0 to
24.9 kg/m2 and recommended a BMI of less than 25 kg/
m2 [54]. Unfortunately, there are no Korean-specific data
on appropriate waist circumference. A waist circumfer-
ence of less than 90 cm for men and 80 cm for women is
recommended for Asian individuals [55].
The recommendations for weight reduction are to eat
breakfast every morning, eat slowly, and avoid a high-
carbohydrate diet, alcohol, snacks such as bread and
cookies, and sweetened beverages. A high-fiber diet is
recommended, and a high-fat diet including food fried
with oil is prohibited. Patients should try to eat as many
fruits and vegetables as possible and to avoid meals con-
taining large amounts of cholesterol and saturated fatty
acids.
Moderation of alcohol consumption
BP tends to increase in patients who drink excessive
amounts of alcohol, and such patients are also resistant
to antihypertensive drugs. An appropriate moderate
daily amount of alcohol is less than 20 to 30 g for men
or 10 to 20 g for women. A man or woman with lower-
than-average body weight is more sensitive to alcohol
and is therefore permitted half of the recommended
amount. Heavy drinkers should be warned that they are
high risk for stroke. One bottle of beer (720 mL), one
glass of wine (range, 200 to 300 mL), one glass of sake
(200 mL), two shots of whisky (60 mL), or two to three
glasses of soju corresponds to 30 g of alcohol.
Exercise
The benefits of regular exercise are lowering of BP, im-
provement of cardiopulmonary function, reduction of
body weight, improvement of the lipid profile (including
elevation of HDL cholesterol), and reduction of emo-
tional stress. Aerobic exercises such as brisk walking,
jogging, bicycling, swimming, jumping rope, playing ten-
nis, and aerobic dancing are recommended for patients
with HTN. The appropriate intensity of exercise is 60%
to 80% of the maximal heart rate (220—age in years).
Such exercise should be performed five to seven times
per week. Aerobic exercise should begin at low intensity
for 10 to 20 min and then increase to appropriate inten-
sity for another 30 to 60 min. Every exercise session
should start with 5 min of warm-up exercise and end
with 5 min of cool-down exercise. In addition to aerobic
exercise, isometric exercise such as weight lifting can re-
duce BP, produce metabolic benefits, and increase
muscle power. Isometric exercise is recommended two
to three times per week [56]. Isotonic exercise such aslifting a heavy object (anaerobic metabolism) can in-
crease BP and may be dangerous in patients with poorly
controlled HTN. Most patients with uncomplicated
HTN can begin regular exercise without an initial evalu-
ation and increase the duration and intensity to appro-
priate levels as possible. However, patients with known
CVDs or other risk factors are recommended to start
the exercise only after complete evaluation by an exer-
cise consultant and to follow a program.
Smoking cessation
During smoking, the BP increases temporarily in response
to nicotine. Among patients with white coat HTN, smokers
maintain a higher daytime ambulatory SBP than do non-
smokers with a similar office BP [57]. Smoking, like HTN,
is a powerful risk factor for CVD [58], and CV events are
inevitable in patients who continue smoking regardless of
BP control. Second-hand smoking is also harmful. Smoking
cessation should be advised at every opportunity. Low-
nicotine-containing replacement materials do not increase
BP and can be recommended in combination with behavior
therapy. During smoking cessation, regular exercise and
diet therapy should be emphasized in order to prevent
weight gain.
Healthy diet management
BP is lower in vegetarians than in people who mainly eat
meat, and maintaining a vegetarian diet can reduce BP.
The BP-lowering effect results not from decreasing the
intake of animal protein but from increasing the intake
of vegetables and fruits in combination with decreasing
the intake of saturated fatty acids. In a study in elderly
people, BP decreased by 3/1 mm Hg when intake of veg-
etables and fruits was increased alone but by 6/3 mmHg
when it was combined with a decrease in fat intake
[59-61]. In patients with HTN, a combined diet with
greater intake of calcium, magnesium, and potassium
decreased BP by an additional 11/6 mm Hg [59,61,62].
A regular diet composed mainly of fish reduces BP and
improves the lipid profile in obese patients with HTN.
The Dietary Approaches to Stop HTN (DASH) diet,
which is rich in vegetables, fruits, and fish and low in
fat, is recommended for patients with HTN [63].
Others
Caffeine from various foods rapidly increases BP, but the
effect does not progress to HTN because tolerance to
caffeine develops. Emotional stress increases both BP
and the risk for CVD, making the control of emotional
stress important for the management and patient com-
pliance of HTN. Further studies are required to examine
the long-term effects of stress control on HTN and
CVD. The effectiveness of various methods of stress
management, such as relaxation and biofeedback, for the
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no clear evidence for the effects of micronutrients, cal-
cium, magnesium, and supplementary fiber on BP.Pharmacological therapy
The occurrence of CV events in patients with HTN can
be decreased by reducing the BP. Currently available an-
tihypertensive drugs are more effective than placebo for
prevention of CVD. This preventive effect is relatively
larger for stroke than for coronary artery disease. The
extent to which CV events are reduced depends on the
degree of BP reduction. All major classes of antihyper-
tensive drugs, including beta-blockers and diuretics, are
suitable for first-line treatment. However, the individual
drug should be prescribed with consideration of the pa-
tient’s individual situation, including age, comorbidities,
and possible adverse effects. Simplifying the medication
schedule, careful monitoring of the adverse effects, and
checking the BP at home are useful for improving pa-
tient compliance and making the patient an active par-
ticipant in the treatment.Strategies for prescription of antihypertensive
drugs
Principles of drug selection
For reduction of long-term CV morbidity and mortality, it
is essential to control most of the modifiable risk factors
and to reduce the BP to less than 140/90 mm Hg [40].
Drug therapy is initiated at a low dose to avoid adverse ef-
fects. The preferred drugs are long-acting and can be
taken only once a day [64]. Drugs with a high trough/peak
ratio (>0.5) are helpful for improving compliance and to
maintain a stable BP with minimal variability [65]. If it is
impossible to control BP with once-daily dosing, a twice-
daily schedule is an alternative option. Angiotensin-
converting enzyme (ACE) inhibitors, angiotensin receptor
blockers (ARBs), calcium antagonists, beta-blockers, and
diuretics are all suitable for initiation of antihypertensive
treatment. The indications, contraindications, comorbidi-
ties, and presence of asymptomatic organ damage should
all be considered in the choice of drug (Table 4). There is
no uniform consensus on the role of beta-blockers in eld-
erly patients with HTN, so prescription of beta-blockers
in the elderly should be limited to special circumstances.
Beta-blockers should also be used with care in patients at
high risk for diabetes because in combination with di-
uretics they can increase the risk of new onset of diabetes
[40]. In patients with BP higher than 160/100 mm Hg or
more than 20/10 mm Hg above the target BP, two drugs
can be prescribed in combination to maximize the antihy-
pertensive effect and achieve rapid BP control [40]. Fixed-
dose single pills have multiple benefits, including maxi-
mizing reduction of BP, minimizing adverse effects,increasing compliance, and preventing CVD and target
organ damage [40].
Selection of drugs
It is reasonable to choose drugs according to the pa-
tient’s comorbidities and clinical characteristics rather
than his or her BP level. There are five available classes
of first-line drugs with proven BP-lowering effects,
safety, and acceptable adverse effects according to mul-
tiple studies. They are: 1) ACE inhibitors or ARBs, 2)
beta-blockers, 3) calcium antagonists, 4) diuretics such
as hydrochlorothiazide, chlorthalidone, or indapamide,
and 5) other drugs (loop diuretics, aldosterone antago-
nists, alpha-blockers, and direct vasodilators). All reduce
BP to a similar extent when the dose has been adjusted.
However, there might be individual differences in BP
lowering, adverse effects, and long-term CV events,
making it very important to choose the appropriate
drugs according to the patient’s combined risk factors
and comorbidities (Table 5). No antihypertensive drug is
inherently superior, and the drugs most appropriate for
the individual patient should be preferred (Table 5).
Classes of antihypertensive drugs
Diuretics
Diuretics decrease BP initially by reducing reabsorption
of sodium in the renal distal convoluted tubules and
later by decreasing peripheral vascular resistance. High-
dose thiazide-derivative diuretics can induce hypokal-
emia, glucose intolerance, hyperuricemia, arrhythmia,
and adverse lipid metabolism, but low doses rarely have
these effects. For decreasing BP, the dose can be in-
creased to 25 mg a day. Combination of diuretics with
beta-blockers is not recommended in patients with obes-
ity or high risk for diabetes because of adverse effects
such as new-onset diabetes and adverse lipid metabol-
ism. No specific thiazide diuretic is recommended over
the others because there has been no study comparing
them directly, although chlorthalidone and indapamide
are reported to be most effective for lowering BP [67].
As thiazide diuretics must frequently be administered at
high doses to achieve optimal BP control, and because
such high doses increase the adverse effects, thiazide-
like diuretics may be preferred to avoid high dosage
and/or reduce metabolic derangement. Spironolactone is
proven effective in patients with heart failure and can
also be considered at low doses (range, 20 to 50 mg) for
treatment of resistant HTN.
Beta-blockers
Selective beta-1 blockers are recommended for patients
with HTN in combination with angina pectoris, myocardial
infarction, or tachycardia. Beta-blockers are also effective
in younger patients who have higher heart rates [40].
Table 4 Compelling indications for choosing the antihypertensive drugs [40,66]
Angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers
Beta-blockers Calcium antagonists Diuretics
Congestive heart failure O O O
Left ventricular hypertrophy O O
Coronary artery disease O O
Diabetic nephropathy O
Stroke O O O
Elderly, isolated systolic hypertension O O O
Post-myocardial infarction O O
Prevention of atrial fibrillation O
Diabetes O
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asthma, chronic obstructive pulmonary disease, second- or
third-degree atrioventricular block, or peripheral vascular
disease [40].
Beta-blockers can have adverse effects on blood glu-
cose and lipid metabolism and should therefore be used
cautiously in elderly patients or patients with elevated
blood sugar, diabetes, or metabolic syndrome [68]. They
should also be used carefully in patients with variant an-
gina because they can worsen symptoms. [69] Because
atenolol is inferior for stroke prevention, first-line ther-
apy is not recommended for elderly patients with HTN
[70]. Concomitant use of beta-blockers and diuretics will
increase the incidence of diabetes and should therefore
be avoided in patients at high risk for developing dia-
betes [68]. Vasodilatory beta-blockers might have differ-
ent effects than atenolol, but no comparative study has
yet been performed [71,72].
Calcium antagonists
Long-acting calcium antagonists are preferable to short-
acting calcium antagonists, which can cause tachycardia
and increase cardiac workload. Because calcium antagonists
have a vasodilatory effect on the coronary artery, they are






Beta-blockers Ischemic heart disease, myocardial infarctio
Calcium antagonists Elderly hypertension, isolate systolic hypert
ischemic heart disease (non-dihydropyridin
calcium antagonists)
Diuretics CHF, isolated systolic hypertension
CHF congestive heart failure.angina, which is caused by coronary artery spasm. They are
also effective for slowing the progression of carotid athero-
sclerosis and reducing cardiac hypertrophy [73]. The non-
dihydropyridine calcium antagonists, verapamil and diltia-
zem, are effective after myocardial infarction because they
do not produce reflex tachycardia. They are also effective in
patients with hypertrophic cardiomyopathy because they
improve diastolic filling. The common side effects of dihy-
dropyridine calcium antagonists are tachycardia, ankle
edema, headache, and facial flushing. Non-dihydropyridine
calcium antagonists may cause constipation, conduction
delay, and decreased myocardial contractility and should
therefore be prescribed cautiously to patients with systolic
heart failure or heart block. In addition, special caution is
needed when administering them in combination with
beta-blockers in elderly patients.
Angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers
ACE inhibitors/angiotensin receptor blockers reduce
mortality in patients with heart failure and help to in-
hibit the progression of renal disease. They also help to
prevent LVH and atherosclerosis but have little effect on
blood glucose or lipid metabolism [74]. In addition, they





















High blood glucose Gout hypokalemia
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hypotensive response in dehydrated or elderly patients
[75]. When administered to a patient with bilateral renal
artery stenosis, they can have adverse effects such as se-
vere hypotension and deterioration of renal function
[75]. The serum creatinine level may increase within the
first 2 months after the start of treatment. However,
there is no need to discontinue the drug unless the
serum creatinine increases to less than 30% rise than the
baseline creatinine level or unless serum potassium is
5.5 mEq/L or higher [76]. Care should be taken in pa-
tients with a serum creatinine level higher than 3.0 mg/
dL [77]. The blood potassium level and renal function
should be checked before and within 1 to 2 weeks after
administration of the drug and then again 3 or 6 months
later. ACE inhibitors inhibit bradykinin degradation and
can thus cause a dry cough, but this resolves within a
few days to a few weeks after stopping the medication.
Dry cough is more common in women and nonsmokers.
Angiotensin receptor blockers have no effect on bradyki-
nin and therefore rarely cause cough. ACE inhibitors/
angiotensin receptor blockers are contraindicated in
pregnant women because of their teratogenic effects on
the fetus.
Others
Alpha-blockers can alleviate urinary symptoms in pa-
tients with prostate enlargement and also improve the
metabolism of sugars and lipids. However, they can
cause orthostatic hypotension and are associated with
worsening of heart failure. Agents that act on the central
nervous system, such as clonidine, methyldopa, and re-
serpine, have many side effects and are therefore notFigure 2 Choice of single drug or combination drugs according to threcommended as first-line drugs. Renin inhibitors have
been developed and used in other countries but have
not yet been introduced in Korea. Renin inhibitors sig-
nificantly reduced BP and proteinuria when used alone
or in combination with diuretics. However, aliskiren has
not been proven to improve the prognosis of patients
with CVD. Methyldopa is still preferred for the treat-
ment of HTN in pregnant women but is not the first
choice because of its side effects. Hydralazine is a vaso-
dilator that is relatively safe for pregnant women with
HTN.
Combination therapy
More than 2/3 of patients with HTN need drugs from
more than two drug classes with different mechanisms
to achieve control of HTN. Combination therapy is par-
ticularly helpful for patients receiving prolonged BP
treatment, high-risk patients, and patients with a low
target BP. If the first drug used is not effective for BP
control, then a drug of another class should be tried. If
the efficacy is insufficient, the dose should be increased
or another drug added. However, it is recommended to
combine two different drugs in smaller doses rather than
to increase the dosage of one drug because such low-
dose combinations lower BP more effectively and im-
prove the compliance while decreasing the adverse ef-
fects (Figure 2) [78].
If BP is not controlled with a single drug, two drugs
should be combined for BP control. Combination therapy
is more effective than single-drug therapy at a higher dose
[78]. However, it has not been fully evaluated which com-
bination is best. Combination therapy chosen from the
renin-angiotensin system inhibitors, calcium antagonists,e level of blood pressure and the global cardiovascular risk.







Using too small cuff
White coat hypertension
Calcified vessel in the elderly (pseudohypertension)
Resistant
hypertension
Lifestyle factors: severe weight gain, heavy or binge
drinking, excess salt intake






Volume expansion by renal diseases
Vascular damage or stiffness
Prescription of antihypertensive drugs: insufficient
dose, wrong use of diuretics, ineffective combination,
drug interaction
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relatively good results [17,79,80], but beta-blockers can
also be combined with drugs of other classes (Figure 3).
However, the combination of beta-blockers and diuretics
can increase the incidence of diabetes and metabolic dis-
orders and thus requires periodic monitoring. Combin-
ation therapy with angiotensin-receptor blockers and ACE
inhibitors may be slightly more effective for reducing pro-
teinuria but increases the risk for end-stage renal failure,
stroke, and other CVD [81-83].
Resistant hypertension
Resistant HTN is defined as BP that cannot be con-
trolled (BP ≥ 140/90 mm Hg) despite treatment with
more than three different classes of antihypertensive
drugs, including diuretics. The prevalence of resistant
HTN is reported to be 5% to 30% in other countries.
However, considering the frequency of pseudo-resistant
HTN, the prevalence of true resistant HTN is assumed
to be less than 10% [40]. Patients with resistant HTN are
at much higher risk for complications such as CVD and
kidney disease [84].
Among the wide range of causes of resistant HTN
(Table 6), noncompliance is the most common. In
addition, medications taken for relief of cold symptoms,
nonsteroidal anti-inflammatory drugs, adrenal cortical
steroids, birth control pills, excessive salt intake, and ex-
cessive alcohol consumption can also cause resistant
HTN. If diuretics have not been included in the regimen,
volume overload can cause resistant HTN. Finally, sec-
ondary HTN can cause resistant HTN. To diagnose re-
sistant HTN, treatment compliance should be confirmed
and then the home BP or ambulatory BP checked in
order to exclude white coat HTN. If BP cannot be con-
trolled despite the use of effective doses of three differ-
ent classes of drug, then the dose of diuretics should be
increased, or amiloride added, or thiazide diureticsFigure 3 Recommended combination therapy, thick lines;
preferred combination, thin line; feasible combination. ARB
angiotensin receptor blocker, ACE angiotensin-converting enzyme.changed to loop diuretics in patients with renal impair-
ment. However, most patients with resistant HTN re-
quire a different mechanism for BP control, and the
fourth drug added should be spironolactone or an alpha-
blocker such as doxazosin [85-88].
Renal denervation
Bilateral destruction of the renal sympathetic nerves that
course along the renal artery by the use of radiofre-
quency ablation catheters is an increasingly popular
nondrug therapeutic approach to HTN. Reduction of BP
lasts for more than a year after the procedure, and the
BP-reducing effect was reported to be maintained for
another 3 years of follow-up [89].
The treatment itself has no significant complications
and can therefore be used in patients with resistant
HTN. However, there is insufficient short-term and
long-term evidence for the efficacy of renal denervation
[90]. Carotid stimulation is also reported to be effective
for lowering BP in patients with resistant HTN; however,
there is very little randomized blind study data support-
ing its efficacy [91].
Reduction or discontinuation of antihypertensive
medications
In patients whose BP has been well controlled for years,
the dose of antihypertensive drug can be reduced. After-
wards, the BP should be checked regularly, and the con-
tinued practice of lifestyle modifications monitored [40].
Shin et al. Clinical Hypertension  (2015) 21:2 Page 10 of 13Other drug treatments
The goal of antihypertensive therapy is to reduce the
overall CV risk in patients who have other risk factors
such as diabetes, dyslipidemia, coronary artery disease,
stroke, and CKD. Accordingly, these other risk factors
should be treated at the same time.
Antiplatelet therapy
Aspirin administration was shown to produce an abso-
lute benefit for the secondary prevention of CVD in pa-
tients with HTN [92]. However, the role of aspirin for
secondary prevention remains a matter of debate.
Low-dose aspirin (100 mg) can be prescribed to patients
in high-risk groups in order to reduce the risk of CVD
[92,93]. Antiplatelet agents should be administered after
the BP is controlled, and patients should be checked peri-
odically for gastrointestinal bleeding.
Lipid-lowering agents
Lipid-lowering agents have a protective effect on high-
risk patients with HTN. Although there is very little
Korean data, a 50% reduction in low-density lipopro-
tein (LDL) cholesterol in patients who had an LDL
cholesterol level ≥130 mg/dL significantly lowered the
risk for CVD [94]. Lowering the LDL cholesterol level
to <100 mg/dL is recommended in hypertension pa-
tients with coronary artery disease or diabetes mellitus
[95]. For hypertension patients with acute coronary
syndrome, LDL should be lowered below 70 mg/dL.
There is evidence for reducing the LDL cholesterol
level to <135 mg/dL in patients with stroke [96]; how-
ever, there is little data regarding the effect of lowering
the LDL cholesterol to <70 mg/dL in such patients.
Glycemic control
Recent clinical studies have shown that aggressive blood
glucose control (a hemoglobin A1C level less than 6.0% or
6.5%) reduces the incidence of ischemic heart disease in
patients with type 2 diabetes; however, there was no sig-
nificant change or even increase in stroke or total mortal-
ity. Therefore, in patients with diabetes, the blood glucose
level should be controlled so that the hemoglobin A1C is
less than 7.0% in most patients and less aggressively (tar-
get hemoglobin A1C of 7.5% to 8.0%) in older patients or
patients with diabetes of long duration, who have in-
creased risk for hypoglycemia [97].
Monitoring and follow-up
Patients should generally be followed up once monthly,
at least until the target BP is achieved. Patients with se-
vere HTN (stage two or more) need more frequent
follow-up. The serum potassium and creatinine levels
should be measured at least one to two times yearly. If
the BP is controlled and stable, then the patient shouldbe followed up every 3 to 6 months. A longer follow-up
interval may be associated with low compliance. There-
fore, patient compliance also must be monitored, and
the need for blood tests should be emphasized to en-
courage attendance at follow-up visits. A longer follow-
up interval to monitor the status of BP control can be
achieved by encouraging home BP measurement.
Compliance
Trust between doctor and patient is the most important
issue in the treatment of HTN, and the patient should
therefore be encouraged to participate in the develop-
ment of the treatment plan. Many patients may have ob-
tained information about various antihypertensive agents
through various routes, so discussion may be necessary.
First, identify the patient’s point of view to determine
the relative importance of efficacy, cost-effectiveness,
and side effects. It is necessary to reduce overall CV risk
as much as possible while maintaining the patient’s com-
pliance. Self-measurement of BP by using home BP
monitoring can improve compliance.
Abbreviations
ACE: Angiotensin-converting enzyme; ARB: Angiotensin receptor blocker;
BMI: Body mass index; BP: Blood pressure; CKD: Chronic kidney disease;
CV: Cardiovascular; CVD: Cardiovascular diseases; DBP: Diastolic blood pressure;
DM: Diabetes mellitus; HDL: High-density lipoprotein; HTN: Hypertension;
KNHANES: Korean National Health and Nutrition Examination Survey; LDL:
Low-density lipoprotein; LVH: Left ventricular hypertrophy; SBP: Systolic blood
pressure.
Competing interests
Preparation of this guideline is financially supported by the Korean Society of
Hypertension. The authors declare that they have no competing interests.
Acknowledgements
On behalf of the committee of the clinical practice guidelines at the Korean
Society of Hypertension, we thank professors Cheol-Ho Kim and Hyeon
Chang Kim for their kind consultations. Additionally, we thank the officials of
the The Korean Society of Internal Medicine, The Korean Geriatrics Society,
The Korean Stroke Society, The Korean Diabetes Association, The Korean
Society of Nephrology, and The Korean Society of Cardiology for their
endorsement of this guideline.
Author details
1Department of Internal Medicine, Hanyang University College of Medicine,
Seoul, Korea. 2Division of Cardiology, Department of Medicine, Cheil General
Hospital, Kwandong University College of Medicine, Seoul, Korea.
3Department of Internal Medicine, School of Medicine, Seoul National
University, Bundang, Korea. 4Department of Internal Medicine, School of
Medicine, Chonnam University, Gwangju, Korea. 5Division of Cardiology,
Department of Internal Medicine, Kyungpook National University School of
Medicine, 130 Dongdeok-ro, 700-721Jung-gu, Daegu, Korea. 6Division of
Cardiology, Department of Internal Medicine, Ewha Womans University
School of Medicine, Seoul, Korea. 7Division of Cardiology, Department of
Internal Medicine, Dongkuk University School of Medicine, Seoul, Korea.
Received: 2 December 2014 Accepted: 23 December 2014
References
1. Lewington S, Clarke R, Qizilbash N, Peto R, Prospective CR, Studies C. Age-
specific relevance of usual blood pressure to vascular mortality: a meta-
analysis of individual data for one million adults in 61 prospective studies.
Lancet. 2002;360:1903–13.
Shin et al. Clinical Hypertension  (2015) 21:2 Page 11 of 132. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al.
Feasibility of treating prehypertension with an angiotensin-receptor blocker.
N Engl J Med. 2006;354:1685–97.
3. Hamada T, Murata T, Narita K, Takahashi T, Wada Y, Kimura H, et al. The
clinical significance of abnormal diurnal blood pressure variation in healthy
late middle-aged and older adults. Blood Press. 2008;17:134–40.
4. Luders S, Schrader J, Berger J, Unger T, Zidek W, Bohm M, et al. The
PHARAO study: prevention of hypertension with the angiotensin-converting
enzyme inhibitor ramipril in patients with high-normal blood pressure: a
prospective, randomized, controlled prevention trial of the German
Hypertension League. J Hypertens. 2008;26:1487–96.
5. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug
treatment be initiated and to what levels should systolic blood pressure be
lowered? A critical reappraisal. J Hypertens. 2009;27:923–34.
6. Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T,
et al. Effects of ramipril and rosiglitazone on cardiovascular and renal
outcomes in people with impaired glucose tolerance or impaired
fasting glucose: results of the Diabetes REduction Assessment with
ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care.
2008;31:1007–14.
7. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al.
Effect of valsartan on the incidence of diabetes and cardiovascular events.
N Engl J Med. 2010;362:1477–90.
8. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood
pressure control in normotensive type 2 diabetic patients on albuminuria,
retinopathy and strokes. Kidney Int. 2002;61:1086–97.
9. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, et al.
Lower target blood pressures are safe and effective for the prevention of
recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201–8.
10. Zanchetti A, Amery A, Berglund G, Cruickshank JM, Hansson L, Lever AF,
et al. How much should blood pressure be lowered? The problem of the
J-shaped curve. J Hypertens Suppl. 1989;7:S338–48.
11. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far
can cardiovascular risk be reduced? J Hypertens. 2009;27:1509–20.
12. MRC trial of treatment of mild hypertension: principal results. Medical
Research Council Working Party. Br Med J (Clin Res Ed). 1985;291:97–104.
13. The Australian therapeutic trial in mild hypertension. Report by the
Management Committee. Lancet. 1980;1:1261–7.
14. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and
the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272–98.
15. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the
prevention of cardiovascular disease: meta-analysis of 147 randomised trials
in the context of expectations from prospective epidemiological studies.
BMJ. 2009;338:b1665.
16. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/
AHA 2011 expert consensus document on hypertension in the elderly: a
report of the American College of Cardiology Foundation Task Force on
Clinical Expert Consensus documents developed in collaboration with the
American Academy of Neurology, American Geriatrics Society, American
Society for Preventive Cardiology, American Society of Hypertension,
American Society of Nephrology, Association of Black Cardiologists, and
European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–114.
17. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, et al. The Felodipine Event
Reduction (FEVER) study: a randomized long-term placebo-controlled trial in
Chinese hypertensive patients. J Hypertens. 2005;23:2157–72.
18. Zhang Y, Zhang X, Liu L, Zanchetti A, Group FS. Is a systolic blood pressure
target <140 mmHg indicated in all hypertensives? Subgroup analyses of
findings from the randomized FEVER trial. Eur Heart J. 2011;32:1500–8.
19. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al.
Treatment of hypertension in patients 80 years of age or older. N Engl J
Med. 2008;358:1887–98.
20. JATOS Study Group. Principal results of the Japanese trial to assess optimal
systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens
Res. 2008;31:2115–27.
21. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al.
Target blood pressure for treatment of isolated systolic hypertension in the
elderly: valsartan in elderly isolated systolic hypertension study.
Hypertension. 2010;56:196–202.
22. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects
of intensive blood pressure reduction on myocardial infarction and stroke in
diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29:1253–69.23. Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH, Cutler JA,
et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus.
N Engl J Med. 2010;362:1575–85.
24. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al.
Effects of intensive blood-pressure lowering and low-dose aspirin in
patients with hypertension: principal results of the hypertension optimal treat-
ment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.
25. PATS Collaborating Group. Poststroke antihypertensive treatment study. A
preliminary result. Chin Med J (Engl). 1995;108:8.
26. Progress Collaborative Group. Randomised trial of a perindopril-based
blood-pressure-lowering regimen among 6,105 individuals with previous
stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.
27. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary
prevention of stroke and other vascular events: a systematic review. Stroke.
2003;34:2741–8.
28. Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, et al. Level
of systolic blood pressure within the normal range and risk of recurrent
stroke. JAMA. 2011;306:2137–44.
29. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al.
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J
Med. 2008;359:1225–37.
30. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in
stable coronary Artery disease Investigators. Efficacy of perindopril in
reduction of cardiovascular events among patients with stable coronary
artery disease: randomised, double-blind, placebo-controlled, multicentre
trial (the EUROPA study). Lancet. 2003;362:782–8.
31. Poole-Wilson PA, Lubsen J, Kirwan BA, Van Dalen FJ, Wagener G, Danchin N,
et al. Effect of long-acting nifedipine on mortality and cardiovascular
morbidity in patients with stable angina requiring treatment (ACTION trial):
randomised controlled trial. Lancet. 2004;364:849–57.
32. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al.
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
N Engl J Med. 2004;351:2058–68.
33. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The
effects of dietary protein restriction and blood-pressure control on the
progression of chronic renal disease. Modification of Diet in Renal Disease
Study Group. N Engl J Med. 1994;330:877–84.
34. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al.
Effect of blood pressure lowering and antihypertensive drug class on
progression of hypertensive kidney disease: results from the AASK trial.
JAMA. 2002;288:2421–31.
35. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M,
et al. Blood-pressure control for renoprotection in patients with non-
diabetic chronic renal disease (REIN-2): multicentre, randomised controlled
trial. Lancet. 2005;365:939–46.
36. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect
of a lower target blood pressure on the progression of kidney disease:
long-term follow-up of the modification of diet in renal disease study. Ann
Intern Med. 2005;142:342–51.
37. Appel LJ, Wright Jr JT, Greene T, Agodoa LY, Astor BC, Bakris GL, et al.
Intensive blood-pressure control in hypertensive chronic kidney disease.
N Engl J Med. 2010;363:918–29.
38. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for
hypertension. Cochrane Database Syst Rev. 2009;8(3):CD004349.
doi:10.1002/14651858.
39. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood
pressure target in chronic kidney disease and proteinuria as an effect
modifier. Ann Intern Med. 2011;154:541–8.
40. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013
ESH/ESC Guidelines for the management of arterial hypertension: the Task
Force for the management of arterial hypertension of the European Society
of Hypertension (ESH) and of the European Society of Cardiology (ESC).
J Hypertens. 2013;31:1281–357.
41. Messerli FH, Kupfer S, Pepine CJ. J curve in hypertension and coronary
artery disease. Am J Cardiol. 2005;95:160.
42. Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton D, Stevens VJ, Young DR,
et al. Effects of comprehensive lifestyle modification on diet, weight, physical
fitness, and blood pressure control: 18-month results of a randomized trial.
Ann Intern Med. 2006;144:485–95.
43. 2010 Korean National Health Statistics. 2010 Korean National Health and
Nutrition Examination Survey. 2010.
Shin et al. Clinical Hypertension  (2015) 21:2 Page 12 of 1344. Park S, Park JB, Lakatta EG. Association of central hemodynamics with
estimated 24-h urinary sodium in patients with hypertension. J Hypertens.
2011;29:1502–7.
45. He FJ, MacGregor GA. How far should salt intake be reduced? Hypertension.
2003;42:1093–9.
46. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. high-
sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol,
and triglyceride (Cochrane review). Am J Hypertens. 2012;25:1–15.
47. He FJ, Burnier M, Macgregor GA. Nutrition in cardiovascular disease: salt in
hypertension and heart failure. Eur Heart J. 2011;32:3073–80.
48. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM,
Pletcher MJ, et al. Projected effect of dietary salt reductions on future
cardiovascular disease. N Engl J Med. 2010;362:590–9.
49. He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-
analysis of outcome trials. Lancet. 2011;378:380–2.
50. Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt
for the prevention of cardiovascular disease: a meta-analysis of randomized
controlled trials (Cochrane review). Am J Hypertens. 2011;24:843–53.
51. O’Donnell MJ, Mente A, Smyth A, Yusuf S. Salt intake and cardiovascular
disease: why are the data inconsistent? Eur Heart J. 2013;34:1034–40.
52. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al.
Body-mass index and cause-specific mortality in 900 000 adults: collaborative
analyses of 57 prospective studies. Lancet. 2009;373:1083–96.
53. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality
with overweight and obesity using standard body mass index categories: a
systematic review and meta-analysis. JAMA. 2013;309:71–82.
54. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, et al. Body-mass index and
mortality in Korean men and women. N Engl J Med. 2006;355:779–87.
55. International Association for the Study of Obesity. The Asia-Pacific Perspective:
redefining obesity and its treatment.: West Pacific Region WHO. 2000.
56. Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance
training on blood pressure and other cardiovascular risk factors: a meta-
analysis of randomized, controlled trials. Hypertension. 2011;58:950–8.
57. Mann SJ, James GD, Wang RS, Pickering TG. Elevation of ambulatory systolic
blood pressure in hypertensive smokers. A case–control study. JAMA.
1991;265:2226–8.
58. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to
smoking: 40 years’ observations on male British doctors. BMJ. 1994;309:901–11.
59. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A
clinical trial of the effects of dietary patterns on blood pressure, DASH
Collaborative Research Group. N Engl J Med. 1997;336:1117–24.
60. Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller 3rd ER, Lin PH, et al.
Effects on blood lipids of a blood pressure-lowering diet: the Dietary
Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr.
2001;74:80–9.
61. Sacks FM, Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, et al. A
dietary approach to prevent hypertension: a review of the Dietary Approaches
to Stop Hypertension (DASH) Study. Clin Cardiol. 1999;22:III6–III10.
62. Svetkey LP, Simons-Morton D, Vollmer WM, Appel LJ, Conlin PR, Ryan DH,
et al. Effects of dietary patterns on blood pressure: subgroup analysis of the
Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial.
Arch Intern Med. 1999;159:285–93.
63. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary
prevention of cardiovascular disease with a Mediterranean diet. N Engl J
Med. 2013;368:1279–90.
64. Martell N, Gill B, Marin R, Suarez C, Tovar JL, Cia P, et al. Trough to peak
ratio of once-daily lisinopril and twice-daily captopril in patients with
essential hypertension. J Hum Hypertens. 1998;12:69–72.
65. Lipicky RJ. Trough: peak ratio: the rationale behind the United States Food
and Drug Administration recommendations. J Hypertens. 1994;12:S17–8.
discussion S8-9.
66. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al.
Seventh report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. Hypertension.
2003;42:1206–52.
67. National Institute for Health and Clinical Excellence. Hypertension (CG127):
clinical management of primary hypertension in adults. http://wwwniceorguk/
guidance/CG127.
68. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive
drugs: a network meta-analysis. Lancet. 2007;369:201–7.
69. Keller KB, Lemberg L. Prinzmetal’s angina. Am J Crit Care. 2004;13:350–4.70. Campbell NR, Poirier L, Tremblay G, Lindsay P, Reid D, Tobe SW, et al.
Canadian Hypertension Education Program: the science supporting New
2011 CHEP recommendations with an emphasis on health advocacy and
knowledge translation. Can J Cardiol. 2011;27:407–14.
71. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al.
Metabolic effects of carvedilol vs metoprolol in patients with type 2
diabetes mellitus and hypertension: a randomized controlled trial. JAMA.
2004;292:2227–36.
72. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, et al.
Comparative effects of nebivolol and metoprolol on oxidative stress, insulin
resistance, plasma adiponectin and soluble P-selectin levels in hypertensive
patients. J Hypertens. 2006;24:591–6.
73. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al.
Calcium antagonist lacidipine slows down progression of asymptomatic
carotid atherosclerosis: principal results of the European Lacidipine Study on
Atherosclerosis (ELSA), a randomized, double-blind, long-term trial.
Circulation. 2002;106:2422–7.
74. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ,
et al. Reappraisal of European guidelines on hypertension management: a
European Society of Hypertension Task Force document. J Hypertens.
2009;27:2121–58.
75. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation.
1998;97:1411–20.
76. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-
angiotensin-aldosterone system. N Engl J Med. 2004;351:585–92.
77. Bicket DP. Using ACE, inhibitors appropriately. Am Fam Physician. 2002;66:461–8.
78. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy
versus monotherapy in reducing blood pressure: meta-analysis on 11,000
participants from 42 trials. Am J Med. 2009;122:290–300.
79. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects
of a fixed combination of perindopril and indapamide on macrovascular
and microvascular outcomes in patients with type 2 diabetes mellitus (the
ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.
80. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril
plus amlodipine or hydrochlorothiazide for hypertension in high-risk pa-
tients. N Engl J Med. 2008;359:2417–28.
81. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al.
Renal outcomes with telmisartan, ramipril, or both, in people at high
vascular risk (the ONTARGET study): a multicentre, randomised, double-
blind, controlled trial. Lancet. 2008;372:547–53.
82. Parving HH, Brenner BM, McMurray JJ, De Zeeuw D, Haffner SM, Solomon
SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
N Engl J Med. 2012;367:2204–13.
83. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al.
Telmisartan, ramipril, or both in patients at high risk for vascular events.
N Engl J Med. 2008;358:1547–59.
84. Persell SD. Prevalence of resistant hypertension in the United States,
2003–2008. Hypertension. 2011;57:1076–80.
85. Zannad F. Aldosterone antagonist therapy in resistant hypertension.
J Hypertens. 2007;25:747–50.
86. Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR, et al. Effect of
doxazosin gastrointestinal therapeutic system as third-line antihypertensive
therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac
Outcomes Trial. Circulation. 2008;118:42–8.
87. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et al.
Sequential nephron blockade versus sequential renin-angiotensin system
blockade in resistant hypertension: a prospective, randomized, open blinded
endpoint study. J Hypertens. 2012;30:1656–64.
88. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S,
et al. Characterization of resistant hypertension: association between
resistant hypertension, aldosterone, and persistent intravascular volume
expansion. Arch Intern Med. 2008;168:1159–64.
89. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M, et al.
Renal sympathetic denervation in patients with treatment-resistant hyper-
tension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet.
2010;376:1903–9.
90. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al.
A controlled trial of renal denervation for resistant hypertension. N Engl J
Med. 2014;370:1393–401.
91. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al.
Baroreflex activation therapy lowers blood pressure in patients with
Shin et al. Clinical Hypertension  (2015) 21:2 Page 13 of 13resistant hypertension: results from the double-blind, randomized, placebo-
controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765–73.
92. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin
in the primary and secondary prevention of vascular disease: collaborative
meta-analysis of individual participant data from randomised trials. Lancet.
2009;373:1849–60.
93. Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al.
Aspirin is beneficial in hypertensive patients with chronic kidney disease: a
post-hoc subgroup analysis of a randomized controlled trial. J Am Coll
Cardiol. 2010;56:956–65.
94. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ,
et al. Rosuvastatin to prevent vascular events in men and women with
elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
95. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al.
Cholesterol Treatment Trialists, Collaboration. Efficacy and safety of more
intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000
participants in 26 randomised trials. Lancet. 2010;376:1670–81.
96. Amarenco P, Bogousslavsky J, Callahan 3rd A, Goldstein LB, Hennerici M,
Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic
attack. N Engl J Med. 2006;355:549–59.
97. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al.
Management of hyperglycaemia in type 2 diabetes: a patient-centered
approach. Position statement of the American Diabetes Association (ADA)
and the European Association for the Study of Diabetes (EASD).
Diabetologia. 2012;55:1577–96.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
